Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Transcript
With the first 2 anticancer biosimilars having recently entered the market and more waiting to enter, do you think biosimilars will start to play a bigger role in oncology?
I think absolutely. They already have. What we’re seeing on the biosimilar front is actually a greater adoption than most folks thought initially for the non-supportive chemotherapy agents like Avastin, Herceptin, Rituxan. We were thinking maybe a 10% adoption right away. It’s looking more like it’s 15% to 20%. So, I think you’re going to see that trend continue. Biosimilars are going to be here to stay in my opinion and it’s going to be a great opportunity for community oncology.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More